9885

BYU professor co-authors breakthrough cancer research

A new discovery by BYU researchers may help doctors identify and better help patients with genetic potential for chemo and treatment resistance.

BYU and University of Iowa researchers discovered NEK2, a gene that seems to be a predictor of how cancer patients may react to therapy. When NEK2 is highly expressed, patients’ cancers often do not respond to chemotherapy, according to the study published in January in the journal Cancer Cell.

Read the rest of this story at deseretnews.com
Comments and feedback can be sent to feedback@ldsliving.com